The Recall Desk
SevereFDA (Drugs)·D-0444-2024·Announced 2024-04-24

Atovaquone Oral Suspension Recalled Due to Potential Bacillus Contamination

AvKARE recalls Atovaquone Oral Suspension due to potential Bacillus cereus contamination of a non-sterile product. The recalled lot (AW0221A, Exp. 08/30/2025) was distributed nationwide; 153 cartons affected.

What this means for you

Illness, injury, or structural failure has been reported. Stop using the product immediately and contact the manufacturer for a refund or repair.

Our severity reasoning: FDA Class I classification establishes this as Severe (4) per the rubric. No deaths or serious injuries are reported, so the score does not reach Critical (5).

Plain-English summary

AvKARE, Inc. is recalling Atovaquone Oral Suspension USP, 750 mg per 5 mL sachets (NDC 50268-086-12) due to potential Bacillus cereus contamination of the non-sterile product.

The recalled lot is AW0221A with an expiration date of 08/30/2025. A total of 153 cartons were distributed throughout the United States.

Bacillus cereus is a pathogenic microorganism capable of causing infection.

The recalled product

Product
Atovaquone Oral Suspension USP, 750 mg per 5 mL sachets, 20 Units x 5 mL cartons, Rx Only, Manufactured for: AvKARE, Pulaski, TN 38478, NDC 50268-086-12.
Manufacturer
AvKARE
Affected units
153

Is your product affected?

Check your packaging against the codes below. If any of them match, the product is part of this recall.

Lot numbers (1)

  • Lot: AW0221A Exp. 08/30/2025

Distribution

Distributed nationwide across the United States.